IQVIA provides biopharmaceutical development services and commercial outsourcing services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through two segments, Product Development and Integrated Healthcare Services. The company was founded in 1982 and is based in Durham, North Carolina.
IQV Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for IQV, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Iqvia Holdings Inc ranked in the 44th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for IQV, they are:
The company's compound free cash flow growth rate over the past 5.7 years comes in at 0.24%; that's greater than 64.17% of US stocks we're applying DCF forecasting to.
Relative to other stocks in its sector (Healthcare), Iqvia Holdings Inc has a reliance on debt greater than 67.53% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Iqvia Holdings Inc? See DXCM, MCK, HBIO, AMED, and AMGN.
IQVIA™ (NYSE: IQV) today introduced OCE Optimizer, an innovative solution that empowers life sciences companies to plan and refine marketing engagements with healthcare providers (HCPs) on demand. OCE Optimizer extends IQVIA’s Orchestrated Customer Engagement solution by intelligently allocating commercial resources and interaction channels for more effective connections.
IQVIA™ (NYSE: IQV) announced a new Human Data Science Research Collaborative initiative that is waiving licensing and access fees for approved academic researchers around the world to use two IQVIA data technology platforms and analytics from multiple countries to accelerate research addressing challenges and opportunities for health systems in the COVID-19 era.